Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 240.27% | 100.98% | 111.31% | 82.59% | 74.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 386.73% | 326.84% | 647.64% | 1,315.68% | 549.12% |
| Operating Income | -386.73% | -326.84% | -647.64% | -1,315.68% | -549.12% |
| Income Before Tax | -265.86% | -15,429.38% | -423.06% | -2,355.60% | -382.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -265.86% | -15,429.38% | -423.06% | -2,355.60% | -382.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -265.86% | -15,429.38% | -423.06% | -2,355.60% | -382.70% |
| EBIT | -386.73% | -326.84% | -647.64% | -1,315.68% | -549.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -168.50% | -12,366.67% | -223.68% | -1,522.61% | -206.18% |
| Normalized Basic EPS | -168.60% | -12,238.89% | -223.61% | -1,522.55% | -206.21% |
| EPS Diluted | -168.05% | -12,366.67% | -226.20% | -1,565.48% | -203.53% |
| Normalized Diluted EPS | -168.60% | -13,342.42% | -223.61% | -1,522.55% | -206.21% |
| Average Basic Shares Outstanding | 36.25% | 25.88% | 61.65% | 58.70% | 57.68% |
| Average Diluted Shares Outstanding | 36.25% | 16.86% | 61.65% | 58.70% | 57.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |